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are commonly used for the treatment of osteo-
arthritis (OA). These drugs are recognized as often
relieving the symptoms of OA. Nevertheless,
several types of NSAIDs (e.g., sodium salicylate)
inhibit the synthesis of proteoglycans (PGs) and
collagens by chondrocytes in vitro. Hence, they
may diminish the potential of cartilage repair in
OA.
These in-vitro observations are compatible with
in-vivo studies suggesting that some NSAIDs (e.g.,
aspirin), accelerate the progression of OA. There-
fore, it is important to determine the e#ects of a
new NSAID on the anabolic functions of chondro-
cytes. Since there are no validated non-invasive
methods for quantifying the anabolic and cata-
bolic activities of cartilage in vivo, much informa-
tion on the adverse e#ects of NSAIDs on
chondrocyte functions can be obtained by in-vitro
methods using cartilage tissue or di#erentiated
chondrocytes. The aims of in-vitro studies should
be the screening of the e#ects of NSAIDs on
chondroformation and chondroresorption pro-
cesses but also on cytokines activity and synthesis
and by this way allow the classification of these
drugs according their pharmacological in-vitro
e#ects.
Dingle and collaborators [1] have divided
NSAIDs in three categories, with respect to their
in-vitro action upon anabolic functions of OA
cartilage: (1) those such as aceclofenac, which can
stimulate matrix component synthesis; (2) those
such as piroxicam, which express a neutral e#ect
on cartilage anabolism; (3) those like ibuprofen,
naproxen and indomethacin, which significantly
inhibit anabolic functions of chondrocytes. How-
ever, caution must be taken with regard of these
conclusions because they come from short-term
organ culture with plasmatic concentration of
NSAIDs. Moreover, the results vary on isolated
chondrocyte culture systems. Some NSAIDs which
show an anabolic e#ect after short-term treatment,355may have adverse e#ects on cartilage integrity
when administrated during long term treatment or
at higher doses.
Some NSAIDs, such as indomethacin, may exert
their deleterious e#ects on cartilage matrix syn-
thesis by inhibiting prostaglandin E2 (PGE2) pro-
duction [2]. PGE2 have been demonstrated to
enhance collagen and proteoglycan synthesis by
human chondrocytes secondary to the production
of insulin-like growth factor (IGF)-1 [3]. Moreover,
PGE2 inhibits the synthesis of IL-1. IL-1 is the most
important catabolic cytokine in OA, capable of
overcoming the stimulating e#ect of IGF-1 on
matrix components synthesis [4]. Therefore, the
inhibition of PGE2 synthesis by NSAIDs may
induce the release of IL-1 and then inhibit
cartilage matrix protein synthesis (Fig. 1).
Although NSAIDs inhibit PGE2, only some show
an inhibitory e#ect on matrix component syn-
thesis. Other deleterious mechanisms include the
inhibition of glycosyltransferase activity [5], the
uncoupling of mitochondrial oxidative phos-
phorylation [6], the activation of cAMP-dependent
kinase A [7] or the disruption of protein-protein
interactions at the cellular membrane level [8].
On the other hand, the stimulatory e#ect of some
NSAIDs may be related to their inhibitory e#ect
on IL-1 production or IL-1 receptor expression [9]
and thus could promote growth factor activity,
including IGF-1 and TGF-â. Moreover, a number of
NSAIDs, such as tiaprofenic acid, naproxen and
indomethacin, inhibit aggrecans degradation in
cartilage tissue and suppress cartilage breakdown
in animal models of OA. These beneficial actions of
NSAIDs seem to be related to their inhibiting
e#ect on metalloproteinases synthesis and
activity. The metalloproteinase activity may be
modulated by NSAIDs stimulating action on the
production by chondrocytes of tissue inhibitor of
metalloproteases-1 (TIMP-1) or by their inhibiting
action on plasminogen activator synthesis [10].
356 Henrotin and Reginster: In-vitro differences among nonsteroidal antiinflammatory drugsCartilage injury can also be mediated by active
oxygen species (O2
", H2O2, )OH) produced by
chondrocytes and inflammatory cells present in
the synovial membrane. Several NSAIDs, such as
nimesulide, have the faculty to scavenge oxygen
radicals and/or inhibit their production by
NADPH oxidase [11].
Finally, it is interesting to note that NSAIDs
e#ects on chondrocyte metabolic activities widely
vary as a function of the concentration tested, the
age of the donor, the metabolic activity of the
chondrocytes and the severity of cartilage lesions.
It has been reported that osteoarthritic cartilage is
more vulnerable to the influence of NSAIDs than
intact cartilage.
In conclusion, in-vitro research yields valuable
informations on the bioactivity profile of NSAID
drugs on chondrocyte metabolism. Nevertheless,
extrapolation from in vitro to in vivo must be
carried out with caution.FIG. 1. Mechanisms of action of NSAIDs in cartilage anabolism: interaction between catabolic cytokines, growth
factors and prostaglandins. IL-1, Interleukin-1; IGF-1, Insulin-like growth factor-1; IGF-BP, Insulin-like growth factor
binding protein; cAMP, Cyclic adenosine monophosphate.References
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